Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 20, 2026American Journal of Respiratory and Critical Care Medicine

C96-01 Zelicapavir Reduces Symptom Duration and Hospitalization in a Randomized, Double-Blind, Placebo-Controlled, International, Phase 2 Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

CHC E HarrisJDJ P DeVincenzoSCS Chen

Discussion

Loading...

Member takes

Overview

Randomized trial shows zelicapavir improves symptom resolution in high-risk adults with RSV, suggesting a new treatment option.

Key Points

  • This research aimed to evaluate the efficacy of zelicapavir in reducing symptom duration and hospitalization in high-risk adults with RSV.
  • Randomized, double-blind, placebo-controlled study
  • Enrolled 186 RSV PCR positive, symptomatic high-risk outpatients within 3 days of symptom onset
  • Zelicapavir or placebo administered daily for 5 days, with assessments for 28 days
  • Zelicapavir achieved a 2.2-day improvement in symptom resolution for the efficacy population, 6.7 days for the HR3 population
  • Time to improvement of symptoms was 2 days faster in zelicapavir-treated subjects (p = 0.0446)
  • Fewer hospitalizations occurred in the zelicapavir group, with one RSV-related death in the placebo group

Cite This Study

Harris et al. (2026) studied this question.

synapsesocial.com/papers/6a0d4f62f03e14405aa9ab53https://doi.org/10.1093/ajrccm/aamag162.4516
View Full Paper
Ask AI
Bookmark
Share